Skip to main content
. 2022 Sep 4;23(17):10130. doi: 10.3390/ijms231710130

Figure 7.

Figure 7

Comparison of the swimming ability and survivability after intraperitoneal injection of carboxymethyllysine (CML) with Infliximab (Remsima), Tocilizumab (Actemra), or CIGB-258 (Jusvinza). (A) Percentage of swimming zebrafish after injection of CML with Infliximab (Remsima), Tocilizumab (Actemra), or CIGB-258 at 30 min and 60 min post-injection. *** p < 0.001 versus CML + PBS. (B) Survivability of zebrafish at 60 min post-injection of CML with Infliximab (Remsima), Tocilizumab (Actemra), or CIGB-258. *** p < 0.001 versus CML + PBS. (C) Still image of swimming pattern of zebrafish after 30 min and 60 min post-injection of CML with Infliximab (Remsima), Tocilizumab (Actemra), or CIGB-258 at 30 min and 60 min post-injection.